J
J.P. Donnelly
Researcher at Radboud University Nijmegen
Publications - 110
Citations - 10656
J.P. Donnelly is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Transplantation & Mucositis. The author has an hindex of 46, co-authored 110 publications receiving 9865 citations. Previous affiliations of J.P. Donnelly include Hammersmith Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples.
TL;DR: Results confirm that the sandwich ELISA appears to be useful for the early diagnosis of invasive aspergillosis and the value of the test for monitoring the response to antifungal treatment remains to be established in prospective trials.
Journal Article
A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients.
TL;DR: The scheme offers the potential for exploring causal relationships between mucosal damage, granulocytopenia, fever and bacteraemia and can be included as an independent measure in studies of prevention and therapy of complications related to mucositis.
Journal ArticleDOI
Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated
Deborah S. Yokoe,C. Casper,Erik R. Dubberke,Grace M. Lee,Patricia Muñoz,Tara N. Palmore,Kent A. Sepkowitz,Jo Anne H. Young,J.P. Donnelly +8 more
TL;DR: Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated and in which these patients are treated is studied.
Journal ArticleDOI
Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury.
B. van’t Land,Nicole M. A. Blijlevens,Jurgen A. Marteijn,Sharita Timal,J.P. Donnelly,T. de Witte,L M'Rabet +6 more
TL;DR: The results show that the inhibition of NF-κB does not increase intestinal side effects of the anticancer treatment, suggesting a safe use of curcumin and CAPE in combination with antic cancer treatment.
Journal ArticleDOI
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Paul E. Verweij,M. Mensink,Antonius J. M. M. Rijs,J.P. Donnelly,Jacques F. Meis,David W. Denning +5 more
TL;DR: In-vitro resistance of A. fumigatus to the tested antifungal agents was uncommon and the MICs of itraconazole were half those of voriconazole (P < 0.01).